PHARMACEUTICAL COMPOSITION CONTAINING POLYPEPTIDE FRAGMENTS OF SERRALYSINS

The invention relates to a composition that can inhibit the growth of tumour cells of different histological origins and activated endothelial cells. The components of said composition are polypeptide fragments of serralysins, corresponding to the C-terminal fragment, from the internal methionine of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: CASTELLANOS SERRA, LILIA ROSA, BEQUET ROMERO, MONICA, VELIZ RIOS, GLORIA, GARCIA SUAREZ, JOSE, GOMEZ RIERA, RAUL, GAVILONDO COWLEY, JORGE VICTOR, REYES GONZALEZ, JESUS, ABRAHANTES PEREZ, MARIA DEL CARMEN, MARTINEZ DIAZ, EDUARDO, SELMAN-HOUSEIN SOSA, MANUEL, GASMURI, GONZALEZ, CARIDAD ANAIS, GONZALEZ LOPEZ, LUIS JAVIER
Format: Patent
Sprache:eng ; spa
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The invention relates to a composition that can inhibit the growth of tumour cells of different histological origins and activated endothelial cells. The components of said composition are polypeptide fragments of serralysins, corresponding to the C-terminal fragment, from the internal methionine of the sequence to the end of the molecule, which can be combined with one another and, optionally, with prodigiosins which potentiate the anti-tumour effect of the composition. The prodigiosins in the composition can be at a concentration of between 0.1 - 100 nM. The anti-proliferative action of the composition is provided by apoptotic mechanisms. The in vivo administration of the inventive composition has an anti-tumour effect, an anti-angiogenic effect and protects against malignant tumours. La presente invencion esta relacionada con una composicion capaz de inhibir el crecimiento de celulas tumorales de diferentes origenes histologicos y de celulas endoteliales activadas; los componentes de dicha composicion son fragmentos polipeptidicos de Serralisinas, correspondientes al fragmento C-terminal, a partir de la metionina interna de la secuencia hasta el final de la molecula, los cuales pueden combinarse entre ellos y opcionalmente con prodigiosinas que potencian el efecto anti-tumoral de la composicion; las prodigiosinas en la composicion pueden estar a una concentracion de 0.1 - 100 nM; la accion anti-proliferativa de la composicion esta mediada por mecanismos apoptoticos. Su administracion "in vivo" tiene efecto antitumoral, antiangiogenico y protector contra tumores malignos.